202 related articles for article (PubMed ID: 25801155)
1. Ligand selectivity of a synthetic CXCR4 mimetic peptide.
Groß A; Brox R; Damm D; Tschammer N; Schmidt B; Eichler J
Bioorg Med Chem; 2015 Jul; 23(14):4050-5. PubMed ID: 25801155
[TBL] [Abstract][Full Text] [Related]
2. Mimicking Protein-Protein Interactions through Peptide-Peptide Interactions: HIV-1 gp120 and CXCR4.
Groß A; Möbius K; Haußner C; Donhauser N; Schmidt B; Eichler J
Front Immunol; 2013; 4():257. PubMed ID: 24027570
[TBL] [Abstract][Full Text] [Related]
3. Exploring converse molecular mechanisms of anti-HIV-1 antibodies using a synthetic CXCR4 mimic.
Haussner C; Möbius K; Eichler J
Bioorg Med Chem Lett; 2012 Oct; 22(19):6099-102. PubMed ID: 22939235
[TBL] [Abstract][Full Text] [Related]
4. Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.
Choi WT; Tian S; Dong CZ; Kumar S; Liu D; Madani N; An J; Sodroski JG; Huang Z
J Virol; 2005 Dec; 79(24):15398-404. PubMed ID: 16306611
[TBL] [Abstract][Full Text] [Related]
5. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.
Chevigné A; Fievez V; Szpakowska M; Fischer A; Counson M; Plesséria JM; Schmit JC; Deroo S
Biochim Biophys Acta; 2014 May; 1843(5):1031-41. PubMed ID: 24480462
[TBL] [Abstract][Full Text] [Related]
6. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
Yonezawa A; Hori T; Takaori-Kondo A; Morita R; Uchiyama T
J Virol; 2001 May; 75(9):4258-67. PubMed ID: 11287575
[TBL] [Abstract][Full Text] [Related]
7. N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins.
Wang J; Babcock GJ; Choe H; Farzan M; Sodroski J; Gabuzda D
Virology; 2004 Jun; 324(1):140-50. PubMed ID: 15183061
[TBL] [Abstract][Full Text] [Related]
8. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
Verrier F; Borman AM; Brand D; Girard M
AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
[TBL] [Abstract][Full Text] [Related]
9. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor.
Fenard D; Lambeau G; Maurin T; Lefebvre JC; Doglio A
Mol Pharmacol; 2001 Aug; 60(2):341-7. PubMed ID: 11455021
[TBL] [Abstract][Full Text] [Related]
10. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
11. Functional mimetic of the G-protein coupled receptor CXCR4 on a soluble antibody scaffold.
Koksal AC; Pennini ME; Marelli M; Xiao X; Dall'Acqua WF
MAbs; 2019; 11(4):725-734. PubMed ID: 30900513
[TBL] [Abstract][Full Text] [Related]
12. Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains.
Tian S; Choi WT; Liu D; Pesavento J; Wang Y; An J; Sodroski JG; Huang Z
J Virol; 2005 Oct; 79(20):12667-73. PubMed ID: 16188969
[TBL] [Abstract][Full Text] [Related]
13. Glycans and proteoglycans are involved in the interactions of human immunodeficiency virus type 1 envelope glycoprotein and of SDF-1alpha with membrane ligands of CD4(+) CXCR4(+) cells.
Mbemba E; Benjouad A; Saffar L; Gattegno L
Virology; 1999 Dec; 265(2):354-64. PubMed ID: 10600606
[TBL] [Abstract][Full Text] [Related]
14. Anti-HIV-1 peptide derivatives based on the HIV-1 Co-receptor CXCR4.
Hashimoto C; Nomura W; Narumi T; Fujino M; Tsutsumi H; Haseyama M; Yamamoto N; Murakami T; Tamamura H
ChemMedChem; 2013 Oct; 8(10):1668-72. PubMed ID: 24039179
[TBL] [Abstract][Full Text] [Related]
15. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMIP-II.
Zhou N; Luo Z; Luo J; Hall JW; Huang Z
Biochemistry; 2000 Apr; 39(13):3782-7. PubMed ID: 10736178
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 gp120-CXCR4 recognition probed with synthetic nanomolar affinity D-peptides containing fragments of gp120 V3 loop.
Zhu R; Meng Q; Zhang H; Zhang G; Huang LSM; Xu Y; Schooley RT; An J; Huang Z
Eur J Med Chem; 2022 Dec; 244():114797. PubMed ID: 36270088
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 envelope is a neutral antagonist to CXCR4 in T-cells.
Staudinger R; Wang X; Bandrés JC
Biochem Biophys Res Commun; 2001 Feb; 280(4):1003-7. PubMed ID: 11162626
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.
Murakami T; Zhang TY; Koyanagi Y; Tanaka Y; Kim J; Suzuki Y; Minoguchi S; Tamamura H; Waki M; Matsumoto A; Fujii N; Shida H; Hoxie JA; Peiper SC; Yamamoto N
J Virol; 1999 Sep; 73(9):7489-96. PubMed ID: 10438838
[TBL] [Abstract][Full Text] [Related]
19. Design of HIV Coreceptor Derived Peptides That Inhibit Viral Entry at Submicromolar Concentrations.
Bobyk KD; Mandadapu SR; Lohith K; Guzzo C; Bhargava A; Lusso P; Bewley CA
Mol Pharm; 2017 Aug; 14(8):2681-2689. PubMed ID: 28494151
[TBL] [Abstract][Full Text] [Related]
20. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Mosi RM; Anastassova V; Cox J; Darkes MC; Idzan SR; Labrecque J; Lau G; Nelson KL; Patel K; Santucci Z; Wong RS; Skerlj RT; Bridger GJ; Huskens D; Schols D; Fricker SP
Biochem Pharmacol; 2012 Feb; 83(4):472-9. PubMed ID: 22146583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
